Prescription drug · BLA
Ocrevus (ocrelizumab) NDC 50242-150
Ocrelizumab 300 mg/10mL · Injection · Intravenous · Genentech, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50242-150-01 | 50242015001 | 1 VIAL, SINGLE-USE in 1 CARTON (50242-150-01) / 10 mL in 1 VIAL, SINGLE-USEMarketed from Mar 28, 2017 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Ocrevus
- Generic name (nonproprietary)
- ocrelizumab
- Active ingredients
- Ocrelizumab — 300 mg/10mL
- Dosage form
- Injection
- Route
- Intravenous
- Labeler
- Genentech, Inc.
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761053
- Marketing start
- Listing expires
- Other FDA classes
- Monoclonal (Chemical structure)Humanized (Chemical structure)CD20-directed Antibody Interactions (Mechanism)
- Identifiers
- Product ID 50242-150_00b80381-c728-47a0-bd9e-b1223a1c0a40SPL ID 00b80381-c728-47a0-bd9e-b1223a1c0a40SPL set ID 9da42362-3bb5-4b83-b4bb-b59fd4e55f0dRxCUI 1876380, 1876385UNII A10SJL62JY
- Pharmacologic class
- CD20-directed Cytolytic Antibody
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N450242015001followed by a unit qualifier and the quantityPackage 50242-0150-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more. OCREVUS is a CD20-directed cytolytic antibody indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 ) Primary progressive MS, in adults ( 1 ) Relapsing-remitting MS, in pediatric patients 10 years of age and olde…
Excerpt only. Read the full label for complete information.